Biogen Inc.'s Stock Analysis

Biogen Reports Significant Expenses Impacting Future Earnings Per Share

Biogen expects to incur approximately $164 million in acquired in-process research and development expenses for the second quarter of 2026, which will affect both GAAP and non-GAAP net income per diluted share by about $0.95. For the third quarter of 2026, the company anticipates expenses ranging from $290 million to $320 million, impacting earnings per share by approximately $1.75 to $1.95. These expenses are related to collaboration and license agreements, including upfront and milestone payments.

The financial results for the quarter ending June 30, 2026, are still subject to finalization and may differ from these preliminary estimates. Biogen has indicated that it cannot predict the exact timing or magnitude of future expenses related to acquired in-process research and development due to inherent uncertainties. Investors are advised to consider the potential impact of these expenses on the company’s financial performance.

Jul 01, 2026 16:08:37

Biogen Reports Results from 2026 Annual Stockholders Meeting

Biogen Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026. The report includes the final voting results from this meeting, which are pertinent to the company's governance and shareholder decisions.

Jun 10, 2026 16:54:22

Biogen Completes $5.3 Billion Acquisition of Apellis Pharmaceuticals

Biogen has successfully completed its acquisition of Apellis Pharmaceuticals, with the transaction valued at approximately $5.3 billion. Biogen's tender offer included a cash payment of $41 per share and a contingent value right, potentially adding up to $4 based on specific sales milestones. Approximately 82.4% of Apellis' outstanding shares were tendered in the offer, leading to the merger where Apellis became a wholly owned subsidiary of Biogen.

The acquisition is expected to enhance Biogen's revenue and earnings per share growth potential, with contributions from Apellis' commercialized products, EMPAVELI® and SYFOVRE®. These products generated $689 million in net revenue in 2025 and will help Biogen expand into nephrology. The company plans to update its financial guidance in July alongside its Q2 earnings report, reflecting the anticipated benefits of this acquisition.

May 14, 2026 08:31:16

Biogen Reports First Quarter 2026 Financial Results and Guidance

Biogen reported total revenue of $2.5 billion for the first quarter of 2026, reflecting a 2% increase year-over-year. The company's GAAP diluted earnings per share (EPS) rose by 31% to $2.15, while non-GAAP diluted EPS increased by 18% to $3.57. Growth products experienced a 12% year-over-year growth, with notable sales increases for LEQEMBI, SKYCLARYS, and ZURZUVAE. However, revenue from SPINRAZA declined by 12%. The company has updated its full-year 2026 guidance, projecting a mid-single-digit percentage decline in total revenue compared to 2025, alongside expected non-GAAP diluted EPS between $14.25 and $15.25, excluding the impact of the proposed acquisition of Apellis Pharmaceuticals.

The planned acquisition of Apellis is anticipated to enhance Biogen's growth prospects by adding commercialized medicines in immune-mediated retinal disease and nephrology. The transaction is expected to be accretive in 2027, contributing positively to Biogen’s non-GAAP diluted EPS growth through the decade. Additionally, Biogen has secured rights to felzartamab in Greater China, potentially expanding its nephrology franchise. As of March 31, 2026, Biogen reported approximately $4.7 billion in cash and cash equivalents and $6.3 billion in total debt, resulting in a net debt of about $1.5 billion.

Apr 29, 2026 06:05:42

Biogen Reports $34 Million Expense Impacting Q1 Earnings

Biogen anticipates a pre-tax expense of approximately $34 million related to acquired in-process research and development, upfront, and milestone costs for the first quarter of 2026. This charge is expected to affect both GAAP and non-GAAP net income per diluted share by about $0.19. The expenses are associated with collaboration and licensing agreements, including upfront payments and milestone payments.

The results for the quarter ending March 31, 2026, are still preliminary and subject to finalization. There is no assurance that the final results will align with the current estimates. Investors are advised that actual results may differ significantly due to various risks and uncertainties, and they should refer to Biogen's Annual Report and other filings for more information on potential risks.

Apr 06, 2026 06:31:37

Biogen Enters Agreement to Acquire Apellis Pharmaceuticals

Biogen Inc. has entered into a definitive Merger Agreement with Apellis Pharmaceuticals, where Biogen's wholly-owned subsidiary will commence a tender offer to acquire all outstanding shares of Apellis Common Stock at $41.00 per share in cash, along with a contingent value right that could yield additional payments based on future milestones. The offer will last for 20 business days and does not require a stockholder vote to proceed, with the merger expected to close after certain conditions are met, including antitrust approvals and the tender of shares representing more than 50% of Apellis' outstanding stock.

In conjunction with the merger, certain Apellis directors and shareholders, holding approximately 14% of the company's shares, have agreed to tender their shares in support of the transaction. The agreement includes provisions for a termination fee if the merger is not completed by September 30, 2026, and outlines restrictions on Apellis' ability to solicit alternative acquisition proposals. The transaction aims to enhance Biogen's portfolio, and both companies have committed to necessary regulatory filings to facilitate the merger process.

Mar 31, 2026 17:03:19

Biogen Chief Legal Officer to Depart by May 2026

Biogen Inc. announced that Susan H. Alexander, the Chief Legal Officer, will leave the company at the end of May 2026. The company has started the process of searching for her successor.

This leadership change may have implications for the company's legal strategies and overall governance. Investors will be watching the transition closely as the new appointment could influence the company's operations and regulatory compliance.

Mar 11, 2026 17:28:01

Biogen Chair Caroline Dorsa to Retire from Board in 2026

Caroline Dorsa, Chair of Biogen's Board of Directors, has announced that she will not seek re-election at the 2026 Annual Meeting of Stockholders. Her decision is not due to any disagreements regarding the company's operations or policies.

Following Dorsa's announcement, the Board has elected Dr. Maria C. Friere to take over as Chair effective after the Annual Meeting. This leadership transition may impact the company's governance structure moving forward.

Feb 11, 2026 17:07:38

Biogen Reports Q4 2025 Financial Results and 2026 Guidance

Biogen announced its financial results for the fourth quarter and full year 2025, reporting total revenue of $2.3 billion for Q4 and $9.9 billion for the full year. The company recorded a GAAP diluted EPS of $(0.33) for Q4 and $8.79 for the full year, with Non-GAAP diluted EPS of $1.99 for Q4 and $15.28 for the full year, surpassing previous guidance. Growth products contributed significantly, with LEQEMBI sales increasing 54% year-over-year. However, revenue from multiple sclerosis products, excluding VUMERITY, experienced declines, impacting overall revenue performance.

For 2026, Biogen provided financial guidance expecting Non-GAAP diluted EPS to range between $15.25 and $16.25, while total revenue is anticipated to decline by a mid-single-digit percentage compared to 2025. The company highlighted ongoing progress in its late-stage pipeline, including FDA Priority Review for LEQEMBI IQLIK and Breakthrough Therapy Designation for litifilimab. As of year-end 2025, Biogen had approximately $4.2 billion in cash and cash equivalents and $6.3 billion in total debt.

Feb 06, 2026 06:55:01

Biogen Reports $222 Million Expense Impacting Q4 2025 Earnings

Biogen Inc. anticipates a pre-tax expense of approximately $222 million related to acquired in-process research and development, upfront, and milestone expenses for the fourth quarter of 2025. This charge is expected to reduce both GAAP and non-GAAP net income per diluted share by about $1.26 for the quarter.

The company began presenting these expenses as a separate line item in its financial statements starting in the first quarter of 2025. The results for the fourth quarter of 2025 are still subject to finalization and may differ from the current preliminary estimates. Investors are advised to consider the uncertainties surrounding these expenses and their potential impact on the company's financial performance.

Jan 13, 2026 17:38:54